Cobolimab

DRUG5 trials

Conditions

Advanced Cervical CarcinomaCervical CancerDiffuse Intrinsic Pontine Glioma (DIPG)EpendymomaFibrolamellar CarcinomaGlioblastoma Multiforme (GBM)Hepatic TumorsHepatoblastoma

Phase 1

Dose Escalation and Expansion Study of GSK3359609 in Participants With Selected Advanced Solid Tumors (INDUCE-1)

CompletedNCT02723955

GlaxoSmithKlineNeoplasms

Start: 2016-06-23End: 2023-07-05Updated: 2024-12-27

Study of the Safety and Effectiveness of GSK6097608 in Participants With Advanced Solid Tumors

Active, not recruitingNCT04446351

GlaxoSmithKlineNeoplasms

Start: 2020-06-25End: 2026-12-31Updated: 2025-10-27

A Study of Cobolimab Plus Dostarlimab in Pediatric and Young Adult Participants With Cancer

Active, not recruitingNCT06521567

GlaxoSmithKlineDiffuse Intrinsic Pontine Glioma (DIPG), Ependymoma, Fibrolamellar Carcinoma +9

Start: 2025-03-06End: 2026-10-13Target: 83Updated: 2025-11-12

Phase 2

Efficacy Comparison of Cobolimab + Dostarlimab + Docetaxel to Dostarlimab + Docetaxel to Docetaxel Alone in Participants With Advanced Non-small Cell Lung Cancer Who Have Progressed on Prior Anti-PD-(L)1 Therapy and Chemotherapy

Active, not recruitingNCT04655976

GlaxoSmithKlineLung Cancer, Non-Small Cell

Start: 2020-12-08End: 2027-03-30Updated: 2026-07-01

Dostarlimab and Cobolimab in Advanced Cervical Cancer

Active, not recruitingNCT06238635

Meghan SheaAdvanced Cervical Carcinoma, Cervical Cancer, Metastatic Cervical Cancer +2

Start: 2024-03-11End: 2027-07-15Target: 66Updated: 2026-01-13

2024-02-1310 citations

596 AMBER, Part 2B: a phase 1 study of cobolimab plus dostarlimab in patients with advanced/metastatic non-small cell lung cancer (NSCLC) previously treated with anti-PD(L)-1 therapy

Regular and Young Investigator Award Abstracts2023-10-314 citations

Activating Inducible T-cell Costimulator Yields Antitumor Activity Alone and in Combination with Anti-PD-1 Checkpoint Blockade

Cancer Research Communications2023-07-1914 citations

Dostarlimab: A Review.

2022-07-2639 citations

Population pharmacokinetics and exposure–response of anti‐programmed cell death protein‐1 monoclonal antibody dostarlimab in advanced solid tumours

British Journal of Clinical Pharmacology2022-03-3125 citations

488 Phase 1 trial of first-in-class anti-CD96 monoclonal antibody inhibitor, GSK6097608, monotherapy and combination with anti–PD-1 monoclonal antibody, dostarlimab, in advanced solid tumors

Regular and Young Investigator Award Abstracts2021-11-015 citations

Abstract CT033: Inducible T cell costimulatory (ICOS) receptor agonist, feladilimab (FE), alone and in combination (combo) with pembrolizumab (PE): Results from INDUCE-1 relapsed/refractory (R/R) melanoma expansion cohorts (EC)

Cancer Research2021-07-011 citations

Inducible T-cell co-stimulatory (ICOS) receptor agonist, feladilimab (fela), alone and in combination (combo) with pembrolizumab (P): Results from INDUCE-1 urothelial carcinoma (UC) expansion cohorts (ECs).

Journal of Clinical Oncology2021-05-2031 citations

Updated analysis of the inducible T-cell co-stimulatory receptor (ICOS) agonist, GSK3359609 (GSK609), combination with pembrolizumab (PE) in patients (pts) with anti-PD-1/L1 treatment-naïve head and neck squamous cell carcinoma (HNSCC).

Journal of Clinical Oncology2020-05-2017 citations

INDUCE-1: Report on safety run-in cohorts combining Inducible T-cell co-stimulatory receptor (ICOS) agonist GSK3359609 (GSK609) with platinum+5-FU chemotherapy (5-FU/plat), with or without pembrolizumab (PE), for the treatment of advanced solid tumors.

Journal of Clinical Oncology2020-05-2010 citations

First in human study with GSK3359609 [GSK609], inducible T cell co-stimulator (ICOS) receptor agonist in patients [Pts] with advanced, solid tumors: Preliminary results from INDUCE-1

Annals of Oncology2018-10-0111 citations

Abstract CT039: INDUCE-1: a phase I open-label study of GSK3359609, an ICOS agonist antibody, administered alone and in combination with pembrolizumab in patients with selected, advanced solid tumors

Cancer Research2017-07-017 citations

INDUCE-1: A phase I open-label study of GSK3359609, an ICOS agonist antibody, administered alone and in combination with pembrolizumab in patients with advanced solid tumors.

Journal of Clinical Oncology2017-05-2011 citations

Abstract IA22: Targeting inducible T cell co-stimulator (ICOS) promotes effector T cell function and antitumor response

Cancer Immunology Research2016-10-31

Cobolimab

Sponsors

Conditions

Phase 1

Phase 2

Related Papers